相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS
Simona Soverini et al.
LEUKEMIA (2021)
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study
Simona Soverini et al.
BLOOD (2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph plus ALL
Nicholas J. Short et al.
BLOOD CANCER JOURNAL (2020)
Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper
Simona Soverini et al.
CANCER MEDICINE (2020)
Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia
Carolina Pavlovsky et al.
FUTURE ONCOLOGY (2019)
A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia
Renato Bassan et al.
HAEMATOLOGICA (2019)
Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
Delong Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
H. Pfeifer et al.
LEUKEMIA (2019)
Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group
Josep-Maria Ribera et al.
CANCER (2019)
Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges
Simona Soverini et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Acute Lymphoblastic Leukemia, Version 1.2019 Featured Updates to the NCCN Guidelines
Patrick A. Brown et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study
Aytug Kizilors et al.
LANCET HAEMATOLOGY (2019)
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
Christopher A. Eide et al.
CANCER CELL (2019)
Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
Irene Della Starza et al.
FRONTIERS IN ONCOLOGY (2019)
Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial
Jean-Michel Cayuela et al.
BLOOD (2019)
BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib
Konstantin Byrgazov et al.
HAEMATOLOGICA (2018)
BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib
Konstantin Byrgazov et al.
HAEMATOLOGICA (2018)
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
Michael W. Deininger et al.
BLOOD (2016)
Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Hoelzer et al.
ANNALS OF ONCOLOGY (2016)
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL
Philippe Rousselot et al.
BLOOD (2016)
Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia
Constance Baer et al.
HAEMATOLOGICA (2016)
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients
S. Soverini et al.
LEUKEMIA (2016)
Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia
Constance Baer et al.
HAEMATOLOGICA (2016)
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase
Katerina Machova Polakova et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
Drug Resistance and BCR-ABL Kinase Domain Mutations in Philadelphia Chromosome- Positive Acute Lymphoblastic Leukemia From the Imatinib to the Second- Generation Tyrosine Kinase Inhibitor Era
Simona Soverini et al.
CANCER (2014)
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
Matthew S. Zabriskie et al.
CANCER CELL (2014)
Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy
Don L. Gibbons et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
Simona Soverini et al.
BLOOD (2013)
The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories
Alexander Kohlmann et al.
BLOOD (2013)
BCR-ABL1 kinase domain mutations: Methodology and clinical evaluation
Mary Alikian et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
H. Pfeifer et al.
LEUKEMIA (2012)
The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories
Alexander Kohlmann et al.
BLOOD (2012)
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
Simona Soverini et al.
BLOOD (2011)
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Thomas O'Hare et al.
BLOOD (2011)
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
Simona Soverini et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories
A. Kohlmann et al.
LEUKEMIA (2011)
Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia A Report of the Association for Molecular Pathology
Dan Jones et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2009)
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors
Dan Jones et al.
CANCER (2008)
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
Neil P. Shah et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
Heike Pfeifer et al.
BLOOD (2007)
Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib
S Soverini et al.
CLINICAL CHEMISTRY (2004)
分享论文
